AMC Health wants to get paid when patients stay well

A bathroom scale is an unlikely place to look for a business model. It supplies a number, then leaves the interpretation to somebody else. For a person living with heart failure, however, a change in weight can matter to a care team. The useful question becomes: who sees the change, understands the context, and follows up?

AMC Health has built its business around that sequence. Its territory is the stretch of ordinary life between medical appointments, when a chronic condition keeps developing while the next scheduled visit remains weeks away. The company supplies home-monitoring technology and the clinical services that can turn those readings into care.

The person behind the number

Founder Nesim Bildirici started AMC in 2002 after his father, Gabriel, died from heart failure. The company’s origin story rests on a painfully specific possibility: a care team with a better view of someone’s condition at home might have more opportunity to help.

That possibility requires some unglamorous machinery. AMC identifies eligible populations, enrolls patients, ships personalized device kits and supports participation. Readings reach its platform, where information can be reviewed alongside other clinical data. Depending on the program, clinicians and care managers handle the follow-through.

The company offers four routes for getting measurements out of a home: a smartphone app, a cellular tablet, a cellular modem and telephone-based interactive voice response. Pre-paired devices reduce setup work. The telephone option is a revealing detail. A service intended for older or harder-to-reach patients cannot assume everyone wants another app.

The nurses were already there

One of AMC’s instructive examples began at Geisinger Health Plan in 2008. Geisinger added remote monitoring to an existing heart-failure care-management program. Bluetooth scales and automated telephone questions supplied information about weight and symptoms. The important organizational detail is that the care-management operation already existed.

A 2014 paper in Population Health Management examined claims for enrolled Medicare Advantage members. It reported lower odds of admission and readmission, an 11.3% reduction in cost of care, and an estimated return on investment of 3.3. These were findings from an observational program analysis, so they should travel with their original population and setting.

Doreen Salek, now AMC’s chief clinical officer, worked at Geisinger and helped integrate AMC monitoring into outpatient case management. In contemporary coverage, she described an early lesson with admirable economy: We found out early if we don’t have the doctors involved, we wouldn’t get anywhere.

For a buyer, that is the detail to copy. Decide who reviews incoming information, who can change treatment, and how disagreements or unanswered calls get resolved. Adding a dashboard to an overloaded team leaves those questions intact. Geisinger’s example puts the clinical relationship inside the design.

Then the alerts became the problem

Collect enough measurements and another constraint appears: attention. In January 2026, AMC reported that only 24% of red alerts under its traditional threshold-based system were associated with evidence of clinical deterioration. Nurses still had to address all of them. The limitation was the precision of the signal.

Its proposed response uses patient-specific baselines and patterns across days. AMC described development using more than 15 million readings spanning over six years. It projected a 45% reduction in alert volume and said it would evaluate the framework against controls. That percentage is a projection, not a completed clinical result.

The lesson is practical: test whether a new system helps people make better decisions, and whether reducing noise preserves safety. More data can create more work. Someone has to measure that work, too.

From sending signals to owning the next step

AMC’s market includes health plans, health systems and government programs, including Veterans Affairs. Its CareConsole software has FDA Class II clearance; the FDA records a September 2024 decision. That regulatory status describes a medical device. Clinical and financial claims still need their own evidence.

Its expertise also attracts partners. GE Healthcare announced a collaboration in 2022 to extend monitoring from hospital to home. York Private Equity made a growth investment in 2021, supporting expansion and product development. In 2024, AMC announced integration of Dexcom continuous glucose-monitoring data, broadening the information available to care teams managing diabetes.

There are credible alternatives. Health Recovery Solutions and Cadence also combine remote monitoring with clinical services. AMC’s case depends on its particular combination of operating history, published program evidence, connectivity choices and clinical execution. Buyers should compare those details against the needs of their own patients.

The operating experience has another application: clinical research. In April and May 2026, AMC announced leadership and advisory appointments for its decentralized clinical trial services. Collecting measurements away from a research site raises familiar operational questions about devices, participation and dependable data. The expansion brings those capabilities to sponsors and contract research organizations.

For health organizations, the buying decision therefore extends beyond software features. They are choosing how much of a care operation to run themselves and how much to obtain from a partner. AMC offers technology, care management and primary care at different levels of clinical responsibility.

The bill follows the result

In October 2026, AMC introduced a performance-based Accountable Primary Care model for high-risk Medicare Advantage members. Affiliated clinicians can conduct visits, prescribe when appropriate and coordinate care, working alongside an existing primary-care physician or assuming that role when one is absent.

The offer removes implementation, platform and fixed program fees. Performance compensation depends on validated savings. Medically necessary clinical services remain billable at the plan’s in-network rates and count toward total care costs. AMC announced a $4.2 million annual savings guarantee for a typical 1,000-member cohort, measured against an agreed control group.

The conditions matter. Patients must participate, readings must arrive, clinicians need capacity to respond, and the financial comparison must be agreed in advance. A monitoring program cannot deliver its intended benefit when those connections fail. AMC’s wager is that keeping them working can be valuable enough to pay for itself.